Lovastatin increases exercise-induced skeletal muscle injury

Metabolism: Clinical and Experimental

Volumn 46, Issue 10, 1997, Pages 1206-1210

  Thompson, Paul D ^a   Zmuda, Joseph M ^b   Domalik, Leslie J ^b   Zimet, Richard J ^b   Staggers, Joan ^b   Guyton, John R ^b  

^a HARTFORD HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PROBUCOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENZYME ANALYSIS; ENZYME INHIBITION; EXERCISE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; LIPID BLOOD LEVEL; MALE; MUSCLE INJURY; MYALGIA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; TREADMILL;

EID: 0030777325     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90218-3     Document Type: Article

References (27)

1. Israeli A, Raveh D, Arnon R, et al: Lovastatin and elevated creatine kinase: Results of rechallenge. Lancet 1:725, 1989
2. Bizzaro N, Bagolin E, Milani L, et al: Massive rhabdomyolysis and simvastatin. Clin Chem 38:1504, 1992
3. Corpier CL, Jones PH, Suki WN, et al: Rhabdomyolysis and renal injury with lovastatin use. JAMA 260:239-241, 1988
4. Reaven P: Lovastatin, nicotinic acid and rhabdomyolsis. Ann Intern Med 109:597-598, 1988
5. Ayanian JA, Fuchs SC, Stone RM: Lovastatin and rhabdomyolysis. Ann Intern Med 15:682, 1988
6. East C, Grundy SM, Jones PH: Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 318:47-48, 1988
7. Thompson PD, Gadeleta PA, Yurgalevitch SM, et al: The effects of exercise and lovastatin on serum creatine kinase activity. Metabolism 40:1333-1336, 1991
8. Walravens PA, Greene C, Frerman FE: Lovastatin, isoprenes, and myopathy. Lancet 2:1097-1098, 1989
9. Thompson PD, Nugent AM, Herbert PN: Increases in creatine kinase after exercise in patients treated with HMG-CoA reductase inhibitors. JAMA 264:2992, 1990
10. Boccuzzi SJ, Bocanegra TS, Walker JF, et al: Long-term safety and efficacy profile of simvastatin. Am J Cardiol 68:1127-1131, 1991
11. Chrysanthopoulos C, Kounis N: Rhabdomyolysis due to combined treatment with lovastatin and cholestyramine. Br Med J 304: 1225, 1992
12. Bornheimer JF, Lau YK: Effects of treadmill exercise on total and myocardial creatine phosphokinase. Chest 80:146-148, 1981
13. Newham DJ, Jones DA, Edwards RHT: Large delayed plasma creatine kinase changes after stepping exercise. Muscle Nerve 6:380, 1983
14. Evans WJ, Cannon JG: The metabolic effects of exercise-induced muscle damage. Exer Sport Sci Rev 19:99-125, 1991
15. Delong DM, Delong ER, Wood PD, et al: A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. JAMA 256:2372-2377, 1986
16. Smit KWA, Amelink GJ, de Bruin TWA, et al: Increased human myoglobin and creatine kinase serum levels after standardized exercise during simvastatin treatment. Eur J Clin Invest A31, 1990 (abstr)
17. Jaweed M, Glennon T, Dean M: Serum creatine kinase levels in response to combined lovastatin administration and exercise. Clin Res 41:600A, 1993 (abstr)
18. Medvier G, Pipe A, Davies R, et al: Predictive value of baseline creatine kinase (CK) in the subsequent response to combined simvastatin administration and exercise. Clin Res 41:600A, 1993 (abstr)
19. Contermans J, Smit WA, Bar PR, et al: A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients. Br J Clin Pharmacol 39:135-141, 1995
20. Byrnes WC, Clarkson PM, White JS, et al: Delayed onset muscle soreness following repeated bouts of downhill running. J Appl Physiol 59:710-715, 1985
21. Nosaka K, Clarkson PM, McGuigin ME: A long-lasting adaptation effect by eccentric exercise. Med Sci Sports Exerc 23:659, 1991
22. Laaksonen R, Ojala J-P, Tikkanen MJ, et al: Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 46:313-317, 1994
23. Laaksonen R, Jokelainen K, Laakso J, et al: The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 77:851-854, 1996
24. Waclawik AJ, Lindal S, Engel AG: Experimental lovastatin myopathy. J Neuropathol Exp Neurol 52:542-549, 1993
25. Smith PF, Eydelloth RS, Grossman SJ, et al: HMG-CoA reductase inhibitor-induced myopathy in the rat: Cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 257:1225-1235, 1991
26. Chariot P, Abadia R, Agnus D, et al: Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 94:109-110, 1993
27. Shimomura Y, Suzuki M, Sugiyama S, et al: Protective effect of coenzyme Q10 on exercise-induced muscle injury. Biochem Biophys Res Commun 176:349-355, 1991